Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 14/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 14/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 14/20 | 0.47 |
| ▸ | CFB | P00751 | 2/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | PTGIR | P43119 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789271 | 0.81 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6791315 | 0.81 | CFB (0.61) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6786823 | 0.81 | CFB (0.54) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL8126010 | 0.79 | CFB (0.47) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6781383 | 0.78 | CFB (0.48) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6764478 | 0.76 | NISCH (0.58) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6781877 | 0.76 | CFB (0.46) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6786981 | 0.76 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL8126007 | 0.75 | ADRA2B (0.43) | ADRA2AADRA2BADRA2CCFBADRA1D | |
| SCHEMBL6790720 | 0.75 | CFB (0.46) | ADRA2AADRA2BADRA2CCFBADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723741-B2 | ANALGESICS, SEDATIVES, ANESTHETICS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-6498177-B2 | ALPHA 2 ADRENERGIC RECEPTOR AGONIST; ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-04-25 | — | — | US | disclosed |
| US-6303643-B1 | THERAPY OF MIGRAINE HEADACHE, HYPERTENSION, ALCOHOL WITHDRAWAL, DRUG ADDICTION, RHEUMATOID ARTHRITIS, PRESBYOPIA, ISCHEMIC PAIN, SPASTICITY, DIARRHEA, NASAL CONGESTION, AND URINARY INCONTINENCE BY ADMINISTERING BENZOTHIAZOLE DERIVATIVE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-0900080-A4 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6159998-A | Substituted indoles and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| US-6040451-A | USED AS ANALGESIC, SEDATIVE AND ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| US-5948804-A | ANAESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0900080-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5677321-A | ANESTHETIC PREMEDICATION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997031636-A1 | NOVEL INDOLE AND BENZOTHIAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049239-A1 | Novel indole and benzothiazole derivatives | ADRB2, ADRB1, CNR2 | ADRA2A 5/4885ADRA2B 4/4885ADRA2C 6/4885 |
| US-20030105147-A1 | Benzimidazoles and benzothiazoles and uses thereof | ADRB2, BDKRB2, ADRB1 | ADRA2A 7/4885ADRA2B 4/4885ADRA2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.